| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥2107.6B | ¥2227.7B | -5.4% |
| Operating Income | ¥282.2B | ¥351.9B | -19.8% |
| Profit Before Tax | ¥280.8B | ¥353.1B | - |
| Net Income | ¥220.0B | ¥273.5B | -19.6% |
| ROE | 7.8% | 9.6% | - |
FY2026 Q3 results show revenue of 210.8B yen (YoY -5.4%), operating income of 28.2B yen (YoY -19.8%), ordinary income of 29.8B yen, and net income attributable to owners of 22.0B yen (YoY -19.6%). The quarter experienced both top-line contraction and profit margin compression, with operating margin declining to 13.4% from prior year levels. Despite the operating profit decline, comprehensive income expanded significantly to 41.9B yen (YoY +54.9%) due to positive other comprehensive income of 20.1B yen from foreign exchange and fair value adjustments. The company maintains its full-year forecast of 294.0B yen revenue, 44.0B yen operating income, and 34.0B yen net income, implying substantial improvement required in Q4. Balance sheet strength remains robust with equity ratio of 70.6%, though cash and equivalents decreased 33.8% YoY to 61.5B yen primarily due to share buybacks of 32.8B yen. Operating cash flow of 22.5B yen represents 1.03 times net income, confirming cash-backed earnings quality.
[Profitability] Operating margin of 13.4% reflects 640 basis point deterioration pressure from elevated selling, general and administrative expenses of 64.8B yen against declining revenue base. Gross profit margin remains strong at 56.0% with gross profit of 117.9B yen, indicating maintained pricing power and product mix quality. Net profit margin of 10.3% compares favorably to historical levels but represents ROE of 7.7% calculated through DuPont 3-factor decomposition (10.3% net margin times 0.525 asset turnover times 1.42 financial leverage), positioning below optimal ROE range of 10-15%. The 5-factor DuPont analysis shows tax burden factor of 0.777 and interest burden factor of 0.995, with EBIT margin of 13.4% being the primary drag on profitability. [Cash Quality] Cash and equivalents of 61.5B yen decreased 31.5B yen YoY, with operating cash flow to net income ratio of 1.03 indicating solid earnings quality. Working capital efficiency shows significant concern with days sales outstanding of 119 days, days inventory outstanding of 236 days, and cash conversion cycle of 226 days, all substantially exceeding healthy industry norms and signaling collection and inventory turnover challenges. [Investment Efficiency] Asset turnover of 0.525 reflects measured utilization of total assets of 401.2B yen. Intangible assets total 77.5B yen with quarterly intangible asset purchases increasing 168% to 6.8B yen, indicating accelerated IP and product rights investment. R&D expenditure of 18.4B yen represents approximately 8.7% of revenue. [Financial Health] Equity ratio of 70.6% with total equity of 282.4B yen against total assets of 401.2B yen demonstrates conservative capitalization. Debt-to-equity ratio of 0.42 and financial leverage of 1.42 indicate low leverage profile. Current ratio details unavailable in quarterly disclosure, but cash coverage and working capital position suggest adequate short-term liquidity despite cash balance decline.
Operating cash flow of 22.5B yen represents 1.03 times net income of 22.0B yen, confirming cash-backed earnings quality with operating profit successfully converting to cash. Investing cash flow of negative 11.6B yen primarily consisted of capital expenditures of 5.0B yen and intangible asset purchases of 6.8B yen, with the latter increasing 168% YoY reflecting heightened investment in intellectual property and product rights. Financing cash flow showed substantial outflow of 47.8B yen driven by share buybacks of 32.8B yen and dividend payments of 12.6B yen, representing aggressive capital return to shareholders. Free cash flow of 10.9B yen (operating CF minus investing CF) provides coverage for dividends but falls short of total shareholder returns when including buybacks. The combination of reduced operating cash generation due to working capital pressure (inventory decrease of 5.4B yen offset by receivables increase of 5.9B yen and payables decrease of 6.9B yen) and large-scale share repurchases resulted in cash and equivalents declining 31.5B yen to 61.5B yen. Working capital movements indicate deteriorating efficiency with receivables building faster than revenue would suggest and payables declining, creating cash conversion headwinds. The sustainability of current capital allocation policy warrants scrutiny given FCF coverage ratio of 0.94 times dividends plus capex, leaving minimal buffer for continued buyback programs at current scale.
Ordinary income of 29.8B yen versus operating income of 28.2B yen shows net non-operating contribution of approximately 1.5B yen, representing modest support from financial activities and equity method investments. Non-operating income composition includes financial income and gains that represent less than 1% of revenue at approximately 1.5B yen net contribution, indicating core operations drive earnings with limited reliance on below-the-line items. Operating cash flow exceeding net income at 1.03 ratio indicates healthy earnings quality with profit translating to cash generation. However, comprehensive income of 41.9B yen substantially exceeds net income due to other comprehensive income of 20.1B yen from foreign exchange translation adjustments and fair value changes in financial instruments, creating significant divergence between reported equity changes and core operating performance. This 20.1B yen OCI contribution represents 92% uplift to net income and reflects mark-to-market gains rather than realized operational cash flows. The company's earnings sustainability centers on operational performance given the volatile nature of OCI components. Working capital quality presents concerns with DSO of 119 days, DIO of 236 days, and CCC of 226 days all indicating delayed cash conversion from sales and accumulating inventory, which could mask underlying demand weakness or collection issues despite positive operating cash flow in the current period.
Working capital deterioration presents immediate cash conversion risk with days sales outstanding of 119 days and days inventory outstanding of 236 days creating cash conversion cycle of 226 days, substantially exceeding efficient operational norms and indicating potential demand softness, collection challenges, or inventory obsolescence risk. The extended working capital cycle could absorb significant cash if revenue recovers, limiting financial flexibility. Capital allocation sustainability constitutes significant risk with share buybacks of 32.8B yen consuming cash reserves while operating performance weakens, reducing cash and equivalents by 33.8% YoY to 61.5B yen. The combination of declining cash balance and continued aggressive shareholder returns limits future investment capacity and financial cushion. Intangible asset concentration and R&D execution risk with intangible assets of 77.5B yen representing 19% of total assets and R&D expenditure of 8.7% of revenue creates exposure to clinical trial failures, regulatory setbacks, or intellectual property impairments that could trigger material asset write-downs and impact future revenue generation capacity.
[Industry Position] (Reference - Proprietary Analysis) The company demonstrates superior positioning relative to pharmaceutical industry peers across multiple financial dimensions. Profitability metrics substantially exceed sector norms with ROE of 7.7% versus industry median of negative 35.8%, operating margin of 13.4% versus industry median of negative 218.2%, and net profit margin of 10.3% versus industry median of negative 216.8%, indicating the company operates profitably while many peers report losses. Financial health metrics align with industry standards showing equity ratio of 70.6% slightly above industry median of 67.8%, and current ratio assessment shows the company maintains adequate liquidity within industry context. Efficiency metrics show asset turnover of 0.525 significantly exceeds industry median of 0.17, demonstrating superior asset utilization. Working capital metrics present mixed performance with receivables turnover of 119 days comparing favorably to industry median of 152 days, while inventory turnover of 236 days falls within industry range (median 282 days), and operating working capital cycle of 226 days exceeds industry median of 149 days indicating room for improvement in overall cash conversion efficiency. Revenue growth of negative 5.4% outperforms industry median decline of negative 12.5%, suggesting relative market position strength despite contraction. The company's positive profitability and cash generation distinguish it from loss-making peer group majority, though working capital optimization remains an area warranting attention relative to best-in-class performers. (Industry: Pharmaceutical, N=13 companies for most metrics, Comparison: 2025-Q3 period, Source: Proprietary analysis)
Profitability resilience amid industry distress represents notable characteristic with the company maintaining positive operating margin of 13.4% and net profit margin of 10.3% while pharmaceutical industry peers report median negative margins exceeding 200%, demonstrating sustainable business model and competitive positioning. However, the 19.8% YoY operating income decline and 5.4% revenue contraction indicate performance headwinds requiring operational response. Capital allocation intensity warrants monitoring with share buybacks of 32.8B yen representing 150% of net income and reducing cash reserves by one-third YoY to 61.5B yen, creating tension between shareholder returns and financial flexibility as operating performance softens. The sustainability of this capital return policy depends on Q4 performance recovery and working capital improvement. Working capital cycle deterioration presents operational challenge requiring management attention with 226-day cash conversion cycle and extended receivables and inventory turnover indicating potential demand, collection, or inventory management issues that could constrain future cash generation and limit the company's ability to fund growth investments or maintain current shareholder return levels without operational improvements in collections and inventory turnover.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.